St Petersburg retains status of center of pharma production in Russia
The city of St Petersburg will retain its status as one of the leading centers of pharmaceutical production in Russia, due to the almost doubling of revenue of pharmaceutical companies operating their facilities within the territory of the city this year.
According to a recent report published by Kommersant St Petersburg business paper, the total revenue of residents pharmas of "St Petersburg" special economic zone in January - June 2021 amounted to almost 38 billion roubles ($503 million), which is 88% higher than for the same period in 2020.
That was mainly due to the increase of revenue of its major players, among which are CJSC Biocad, AO Vertex and LLC Novartis Neva – for which the total value amounted to 34.4 billion roubles this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze